As a Senior Principal Data Scientist, Yuan Wang, PhD, uses her strength for uniting different people in her field to drive innovation at UCB, and encourages her team to value the importance of diversity in collaboration. Read her story. 

Last week, UCB researchers from across the country gathered virtually for the PhRMA Researcher Fly-In where more than 70 industry researchers engaged with Members of Congress. Read their stories. 

At UCB, we know we need diverse perspectives and experiences to do our best work. Passionate scientists like Nikita, who exemplify our vision to embrace new knowledge and to work to discover meaningful solutions for patients, are a driving force for innovation at UCB. Stay tuned over the next few weeks to read stories from UCB women researchers who are pushing the boundaries of science. 

UCB is committed to investing in the future generation of leaders. Established in 2017, the UCB Global Regulatory Affairs (GRA) PharmD Fellowship Program, a collaboration with the Industry Pharmacists Organization (IPhO), was designed to provide PharmD graduates with the opportunity to learn and experience all aspects of regulatory affairs under the mentorship of experienced preceptors.

At UCB, we understand our ability to provide impactful solutions patients value begins with our commitment to our employees. As a company, we pride ourselves in the internal resources and programs available to all employees to encourage professional and personal development. We are pleased to introduce a new series here highlighting UCB as an employer. Today we’re shining a spotlight on our internal organization sponsored by Toastmasters International: UCB Speaks.

“They have a band!” Justin Gorman eagerly answered when his wife asked him how his interview with UCB went in May 2017. For Justin, the employee-formed band, UCB Rocks, was not just a unique feature to UCB, but also a way for him to integrate his personal love of music, his career, and his relationships with other colleagues.

Read from Anita Moser, Michael Davis, Dharmendra Sahay as they outline UCB's measured approach to scaling our AI capabilities. The article was originally published in PharmExec.

At UCB, we know to successfully bring value to the lives of patients we need to cultivate a healthy and connected culture within. This is why UCB provides its employees at its U.S. Headquarters in Atlanta, Georgia and across the U.S. with the tools and facilities to prioritize their well-being.

Today, UCB issued the following statement jointly from Camille Lee, Head of U.S. Immunology, and Jeff Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee (a subcommittee of the U.S. Centers for Disease Control and Prevention) to endorse and make public that non-radiographic axial spondyloarthritis (nr-axSpA) will be formally indexed to ICD-10 sub category M46.8; these changes will be effective for diagnoses starting October 1, 2020 and more information is available on the Centers for Medicare & Medicaid Service (CMS) website which outlines the specific coding changes in greater detail:

At UCB, patients are at the heart of everything we do. Read more from Brad Chapman, U.S. Head of Internal Operations and West Ecosystem - Neurology, on how our agile ways of working are helping us keep our commitment to patients, physicians, and the communities we serve in a work-from-home world.